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S_ry 1The cellular pharmacology of a series of C8-linked pyrrolobenzodiazepine dimers with
polymethylene linkers of n = 3-6 (compounds 1-4) has been studied in a range of human tumour cell lines.
The four compounds showed the same pattern of relative activity in five ovarian carcinoma cell lines and one
cervical carcinoma cell line with the order ofIC5o values of 1 < 3<4<2, which correlated with the previously
demonstrated DNA interstrand cross-linking ability of the compounds in plasmid DNA. In human leukaemic
K562 cells the agents produced a block in the G2/M phase of the cell cycle characteristic of cross-linking
drugs, and extensive interstrand cross-linking was observed in cells by alkaline elution with no evidence of
single-strand breaks. Cross-links continued to increase up to 24 h following a 1 h exposure to drug, and no
repair was evident by 48 h. In a series of ovarian and cervical carcinoma cell lines with acquired resistane to
cisplatin no cross-resistance to the most potent compound 1 was observed in two lines whose major
mechanism of resistance to cisplatin was reduced platinum transport. Cross-resistance to 1 was observed in a
cell line (A2780cisR) possessing elevated glutathione, and depletion of intracellular glutathione using D,L-
buthionine-S,R-sulphoximine (BSO) from 10.25 nmol to 2.8 nmol 106 cells reduced the level of resistance
from 11-fold to 2-fold compared with sensitive cells. Cross-linking in the resistant cells was restored to 80% of
the level in the parent line by BSO pretreatment. There was also a correlation between glutathione levels and
sensitivity to 1 measured in several other ovarian cell lines. Compound 1 also showed cross-resistance in the
doxorubicin-resistant cell line 4lMdoxR and partial cross-resistance in CHldoxR cells. Both these lines
possess elevated levels of p170 glycoprotein. Following treatment with 6 Lm verapamil, the resistance in these
lines decreased almost 2-fold and 8-fold respectively.
The pyrrolo(2,I-cJ[1,41benzodiazepines (PBDs) are a group of
naturally occurring anti-tumour antibiotics which includes
anthramycin (Figure 1), DC-81 (Figure 1), tomaymycin and
sibiromycin. They are thought to exert their anti-tumour
activity through covalent binding to the exocyclic-N2 group
ofguanine in the minor groove of DNA (Hurley & Thurston,
1984; Remers, 1988; Thurston, 1993). DNA footprinting and
exonuclease III stop assays have indicated that the drugs
bind in a sequence-selective manner to three base pairs with a
preference for purine-G-purine triplets (Hertzberg et al.,
1986; Hurley et al., 1988).
Recently, two PBD molecules have been joined together
through their C8-positions via a liker to create a novel
bifunctional agent with the ability to alkylate two guanine
residues on opposite strands of DNA in a sequence-selecfive
manner to form an interstrand cross-link (Bose et al., 1992a).
DSB-120 (compound 1, Figure 1) was the first such com-
pound to be synthesised with a linker consisting of three
methylene groups between two DC-81 molecules (Figure 1),
and a series of analogues with linkers of increasing length
(n = 4-6, compounds 2-4, Figure 1) were subsequently syn-
thesised (Bose et al., 1992b). All four PBD dimers have been
shown to be highly cytotoxic against three murine and one
human tumour cell lines in vitro (Bose et al., 1992b), and the
parent compound [1] has shown some activity in murine
tumours in vivo.
Using an agarose gel-based assay, all four dimers were
shown to be highly efficient DNA cross-linking agents with a
rank order of efficiency of 1>3>4>2, which mirrors the
order of cytotoxicity in several cell lines (Bose et al., 1992b).
The most efficient compound (1) was approximately 50- and
300-fold more efficient than the major-groove cross-linking
agents isplatin and melphalan respectively. Molecular
modelling with permutations of d(CGYGXXCYGG)2 sug-
gests that spatial separation of the PBD units in compound 1
is optimal for spanning 6 bp, with a preference for 5'-
PuGATCPy or 5'-PyGATCPu sequences, and that it actively
recognises the embedded d(GATC)2 motif (Bose et al.,
1992a). This represents an enhanced sequence recognition
compared with the monomer unit DC-81 (Figure 1), which
spans only three bases, only two of which are actively recog-
nised (Thurston, 1993). H-NMR examination of a 1:1 adduct
of 1 with d(CICGATCICG)2 has shown that the duplex is
covalently cross-linked symetrically via the minor-groove N2
positions of the guanines with minimal distortion of the
DNA helix. Molecular modelling has predicted that with
compound 3 the extended linker should be optimal to allow
the inclusion of an extra base pair within the cross-linked
sequence, and this has recently been verified m synthetic
oligonucleotides (Smellie et al., 1993).
This paper investigates aspects of the cellular pharma-
cology of this novel series of agents. Cytotoxicity was
assessed in human tumour cell lines, and cross-resistance
patterns studied in cell lines with characterised mechanisms
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of acquired resistance to the clinically used anti-tumour
agents cisplatin and doxorubicin. In addition, DNA damage
and its repair was as in cells at pharmacologically
relevant doses of the agents using the technique of alkaline
elution.
Materials and methods
Cell culture
The human chronic myelogenous leukaemic cell line K562 as
a suspension culture was grown at 37C in an atmosphere of
95% air/5% carbon dioxide in RPMI-1640 containing 10%
heat-inactivated fetal bovine calf serum, antibiotic free.
All other lines (ovarian carcinoma, HX/62, SKOV-3, 41M,
CHI, A2780; cervical carcinoma, HX/155; cisplatin-resistant
sublines, 4lMcisR, CHlcisR, A2780cisR, HX/155cisR;
doxorubicin-resistant sublines, 4lMdoxR, CHldoxR) were
grown as monolayer cultures at 3rC, in an atmosphere of
90% air/10% carbon dioxide in Dulbecco's modified Eagle
medium (DMEM) with 10% FCS as above, 50 Sgml-' gen-
tamicin, 2.5jgml-1 amphotericin B, 2 mM glutamine,
10 gml' insulin and 0.5jLgml-' hydrocortisone. Establish-
ment details and biological properties of these cell lines have
been described previously (Hills et al., 1989; Kelland et al.,
1993).
Drugs and drug treatment
Compounds 1-4 were synthesised as previously described
(Bose et al., 1992b). Drug stock solutions were prepared in
high-performance liquid chromatography (HPLC)-grade
methanol immediately prior to use. The final methanol con-
centration used to treat cells was less than 0.5%, which did
not affect cell viability. For cell cycle analysis and alkaline
elution experiments, exponentially growing cells were treated
with drug for 1 h at 37'C. Drug-containing medium was then
removed by centrifugation and the cells resuspended in drug-
free medium.
incubation time in drug-free medium. Each sample (0.6 x 106
cells in 2.5 ml) was irradiated with X-rays (450 rads) to
introduce a constant frequency of single-strand breaks. Cells
were then layered on 25-mm-diameter, 2pm pore size filters
(Costar Filtration Products, Nucleopore) and lysed with 5 ml
of Sarcosyl lysis solution (0.2% N-lauroysarcosine, 2M
sodium chloride 0.04M EDTA, pH 10). Elution was per-
formed at pH 12.1 in the presence of 0.5 .gml-' proteinase
K at a constant rate of 2mlh'. A cross-link index was
caculated using the formula:
XLI = V (I-Ro)/(l-RI)-1
where Ro and RI are the relative retention values at 12 h of
alkaline elution for control and drug-treated samples respec-
tively.
Glutathione (GSH) determination and cellular depletion by
D,L-buthionine-S,R-sulphoximine (BSO)
A2780 and A2780cisR cells (1-2 x 10') were harvested,
washed twice with cold PBS and lysed by addition of 1.5 ml
of 0.6% sulphosalicycic acid followed by a 10 min incuba-
tion at 4°C (Russo et al., 1986). The supernatant was
obtained for assay following centrifugation (1,200 r.p.m.,
5 min, 4C) and total GSH was determined by the enzymatic
recycling method based on glutathione reductase described
by Griffith (1980). GSH content was expressed as nmol 1-'
cells. Cellular depletion of glutathione was achieved with
BSO (Mistry et al., 1991). After plating and a 12 h attach-
ment period, medium was aspirated and replaced with
medium containing 50 tLM BSO for 24 h prior to treatment
with the test compound as described above.
Modulation ofmultidrug resistance by verapamil
After a 12 h attachment period, medium containing
verapamil was added to cells (CHl, CHDoxR, 41M and 41M
DoxR), at a final concentration of 6tiM for 2 h prior to drug
treatment as described above. The verapamil remained pre-
sent in growth medium during the drug incubation.
Cytotoxicity studies
Drug-induced cytotoxicity was determined using the sulpho-
rhodamine B assay as previously described (Kelland et al.,
1993). Cells were plated at between 5 x 103 and 1 x 10 in
96-well microtitre plates and left overnight for cells to adhere
before drug treatment. After 4 days of continuous drug
exposure, growth inhibition was assessed using sulpho-
rhodamine B protein staining.
Cell cycle determination
Following drug treatment and the appropriate post-
incubation time in drug-free medium, aliquots of 5 x I0W
K562 cells were collected by centrifigation, washed once,
resuspended in ice-cold phosphate-buffered saline (PBS)
(500gl), fixed by dropwise addition of 95% ethanol (2 ml)
and stored at 4'C until use. Cells were subsequently washed
twice in isotonic saline and resuspended in propidium iodide
solution (0.1% sodium citrate, 50pgml-l propidium iodide,
7.51jgml' RNAse, 0.002% NP40). Cells were incubated
with the stain for 45-60 min in the dark at room
temperature. Cell cycle determination was carried out on a
Becton Dickinson FACScan.
Alkaline elution analysis
Analysis of DNA interstrand cross-link formation in K562,
A2780 and A2780cisR cells was carried out using alkaline
elution as described by Kohn et al. (1981). Logarithmically
growing cells were preincubated with 0.01651&Ciml-'
['4C]thymidine (Amersham 250 iCi 5 ml-') overnight and
then resuspended in label-free medium for 1 h. Incubation
with drug was for 1 h followed by the appropriate post-
Results
Cytotoxicity of1-4 in hwnan ovarian and cervical carcinoma
cell lines
Cytotoxicity of compounds 1-4 in five human ovarian car-
cinoma cell lines (HX62, SKOV-3, 41M, CHI and A2780)
and one human cervical carcinoma cell line (HX155) is
shown in Figure 2. These cell lines were chosen on the basis
of their known pattern of inherent sensitivity to the cross-
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Fugwe 2 Cytotoxicity of compounds 1-4 in five human ovanran
carcinoma cell lines (HX62, SKOV-3, 41M, CHl and A2780) and
one human cervical carcinoma cell line (HX155) as determined by
the sulphorhodamine B assay. Results are the mean ± s.d. of at
least three independent experiments.50 M. SMELLIE et al.
linking drug cisplatin and the availability of sublines with
both cisplatin and doxorubicin acquired resistance. The four
compounds showed the same pattern of relative activity im
the six cell lines with IC5o values in the order 1 < 3<4<2.
This order is consistent with that previously reported in the
human leukaemic cell line K562 (Bose et al., 1992b). The
most potent compound (1) was 120-fold more active in the
most sensitive cell line A2780 than in the least sensitive line
HX155. In addition, the differential toxicity between the
most active (1) and least active compound (2) was greatest in
the most sensitive cell lines, CH1 and A2780 (237- and
168-fold respectively), and smallest in the least sensitive
(HX155, 23-fold). For comparison, compound 1 was between
4-fold (HX155) and 80-fold (A2780) more active than cis-
platin under identical conditions.
Effect ofI on the cell cycle
The effect of the most potent compound (1) on the cell cycle
was analysed in the human leukaemic cell line K562 follow-
ing a 1 h exposure (Figure 3). The IC_0 under these condi-
tions is 0.25 9LM. A clear dose-dependent accumulation of
cells in the G/'M phase of the cell cycle was evident at
subtoxic concentrations of drug, and the persistence of the
block was dependent on the drug dose and the time of
post-incubation. Such a block is consistent with the known
action of DNA-damaging and cross-linking agents (Konopa,
1988).
DNA interstrand cross-linking in cells
Compounds 1-4 have previously been shown to be highly
efficient DNA interstrand cross-linking agents in isolated
DNA (Bose et al., 1992b). The ability of compound 1 to
produce interstrand cross-links in K562 cells was investigated
using the technique of alkaline elution. Following a I h
exposure to drug, a dose-dependent increase in cross-linking
is observed with no evidence of DNA single-strand breakage
(Figure 4a). Cross-linking increases with time up to 24 h of
post-incubation, and this level of cross-linking is maintained
at 48 h (Figure 4b). This is in contrast to other cross-linking
agents, such as chlorambucil or cisplatin, which produce a
peak of cross-linking at 6-12 h in the cell line with extensive
repair evident by 24 h (data not shown). At an equimolar
dose of the least active compound (2) no cross-linking was
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observed at any time point. Compounds 3 and 4 produced
cross-links, but at a lower level than 1. Again there was no
evidence of repair at 48 h (data not shown).
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Fge 3 Cell cycle perturbations induced by compound 1 in K562 cells. Incubations were for 1 h at the doses indicated followed
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Effect ofcompounds 1-4 on cisplatin- and
doxorubicin-resistant cell lines
The cytotoxicity of all four compounds was evaluated simul-
taneously in a panel of both cisplatin- and doxorubicin-
sensitive and acquired resistant human tumour cell lines. The
resulting resistance factors (ICv resistant/parent) are listed in
Table I. In the cisplatin-resistant lines compounds 1-4 gave
similar results in that they retained activity in two of the
resistant lines (4lMcisR and HX155cisR), retained partial
activity against the CHlcisR lines, but showed total cross-
resistance with cisplatin in the A2780-resistant line.
In the 41M-doxR line all four compounds showed a similar
level of resistance to doxorubicin itself. With the CHl-
resistant line all compounds showed some cross-resistance,
but this varied from 12-fold (2) to 84-fold (3) compared with
150-fold for doxorubicin itself.
Effect ofBSO pretreatment on the cytotoxicity and DNA
interstrand cross-linking by compound I in the
cisplatin-resistant cell line A2780cisR
Compounds 1-4 showed a similar level of resistance to
cisplatin in the A2780cisR resistant cell line. As this cell line
is known to have elevated glutathione, increased DNA repair
of cisplatin adducts and decreased uptake of cisplatin
(Behrens et al., 1987), the mechanisms involved in the resis-
tance to 1 were investigated further. Following a 1 h
exposure to drug the resistant cell line was approximately
11-fold less sensitive to 1 than the parent (Table II). At 24 h
post incubation the cross-link index was 2.5-fold less in the
resistant line (Table II) following an equimolar dose of drug.
Both a lower extent and slower rate of formation of cross-
links were observed in the resistant line, with no evidence of
DNA repair in either line at 38 h (Figure 5). The level of
glutathione in the resistant line was almost twice that in the
sensitive line (Table II). Following a 24 h non-cytotoxic
pretreatment of the resistant cells with 50 giM BSO,
glutathione levels were reduced to below that in the sensitive
line (Table II). The level of resistance was reduced from
11-fold to 2-fold compared with the sensitive cells, and the
level of cross-linking was increased 2-fold. In contrast, the
level of resistance to cisplatin was only reduced 1.5-fold.
Similar results were also obtained using the intrinsically
cisplatin-resistant SKOV-3 cell line, which has been shown to
have levels of GSH 4-fold higher than cisplatin-sensitive
ovarian carcinoma cells (Mistry et al., 1991). Whereas the
IC5o value of 1 alone was 6.2FiM (2 h exposure), preincuba-
tions for 24 h with 50gM BSO reduced the IC50 value by
7.8-fold to 0.7911M.
Effect ofverapanil on the cytotoxicity ofI in
doxorubicin-resistant lines
Treatment of cells with verapamil decreased the level of
resistance to 1 in both doxorubicin-resistant lines (Table III).
The resistance factors were decreased by 7.6-fold and 1.7-fold
in the CHI pair and 41M pair respectively. These were
somewhat lower than for doxorubicin itself, which decreased
by 17.2-fold and 3.1-fold respectively.
EDsosso
The ranking order of potency of compounds 1-4 was the
same in the five human ovarian and one cervical tumour cell
lines studied in vitro, with the differential being greatest in
the most sensitive cell lines. This same order was previously
reported in three murine lines and the human leukaemic
0.6 -
0.5
, 0.4-
' 0.3
0 10 co
o 0.2-
0.1
I I
0 10 20 30
Post-incubation time (h)
40
Fugwe 5 DNA interstrand cross-link formation in A2780 (open
symbols) or A2780cisR cells (closed symbols) following a I h
exposure to 0.5 jLm compound 1. Results are mean ± s.d. of at
least three experiments.
Table I Resistance factors for compounds 1-4 in cisplatin- and doxorubicin-resistant ovarian and
cervical cancer cell lines
Resistance factore (IC_O resistant/parent)
Cell line pair 1 2 3 4
Cisplatin
4lM/4lMcisR ~ -5 0.6 0.7 0.6 0.8
CHI/CHIcisR 7 2.3 2.1 2.3 2.6
A2780iA2780cisR 11 13.8 8.6 10.2 10.8
HX155/HX155cisR 9 0.4 0.9 0.4 0.5
Doxorubicin
41M,41MdoxR - 7.7 4.2 3.3 5.2 6.3
CHI/CHldoxR - 150 65 12 84 31
"Mean of three independent experiments. Drug exposure was continuous.
Table II Cytotoxicity, glutathione content and DNA interstrand cross-linking in A2780 cells and
the cisplatin-resistant subline with and without depletion of GSH by BSO
IC50a GSHI Cross-link IC5s
Cell line I (nmol 10-6 cells) index' cisplatin
A2780 0.1±0.02 5.8±1 0.5±0.1 0.9+0.2
A2780cisR 1.1 0.2 10.3 1.5 0.2 0.1 7.8 0.9
A2780cisR + BSO 0.2 0.07 2.8 1.1 0.4 0.01 5.3 1
aOne hour exposure to drug, mean ± s.d. of at least three independent determinations. bMean± s.d.
of three determinations. 'Cross-link index at 24 h following a I h exposure to 0.51LM drug.
Mean ± s.d. of three independent experiments.
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Table M Effect of verapamil on the cytotoxicity of 1 in the doxorubicin
(DOX)-resistant lines
Resistance factora
Dox 1
Cell line pair -ver +verb -ver +ver
41M/4lMdoxR 7.7± 1.3 2.5±0.66 3.7±0.8 2.2±0.2
CHI/CHldoxR 150 8.7 80 10.5
aMean of three independent experiments. bCells were treated with 6giM verapamil
(ver) for 2 h prior to drug treatment, and during drug exposure. This dose of
verapamil resulted in no loss of viability in control cells.
K562 line (Bose et al., 1992b). The most potent compound
(1) was found to be between 4- and 80-fold more active than
Isplatin in these cell lines.
The study of Bose et al. (1992a) demonstrated that the
ranking order of cytotoxicity in tumour cell lines was the
same as DNA interstrand cross-linking ability as measured in
plamid DNA using an agarose gel-based technique. These
data strongly suggested that the cytotoxicity of this class of
compounds is associated with the formation of bifunctional
lesions on DNA. The dose- and time-dependent blockage of
cells in the G2/M phase of the cell cycle observed in the
present study is characteristic of DNA-damaging agents
(Konopa, 1988), and, in particular, DNA interstrand cross-
linking agents such as melphalan (Brox et al., 1980) and
cisplatin (Sorenson & Eastman, 1988). The present study also
demonstrated through alkline elution that compound 1 is a
highly efficient DNA interstrand cross-linking agent in cells.
In addition, with compounds 1-4 the level ofcross-linking in
cells at an equimolar dose reflected the order of cytotox-
icities.
DNA interstrand cross-linking has been shown to correlate
with cytotoxicity for different classes of bifunctional
alkylating agents, including nitrogen mustards (Zwelling et
al., 1981; O'Connor & Kohn, 1990; Sunters et al., 1992),
chloroethylnitrosoureas (Erickson et al., 1980ab), dimethane
sulphonates of the busulphan series (Bedford & Fox, 1989)
and cisplatin (Zwelling et al., 1979a, 1981). It is generally
assumed that an interstrand cross-link, if not repaired, would
interfere with the process of DNA replication. DNA repair
has been shown to be an important determinant ofsensitivity
to many cross-linking agents, and the mechanisms involved
are being elucidated (Burt et al., 1991). However, the cross-
linking in cells by 1 showed some important differences
compared with more classical agents such as melphalan and
isplatin, whose kinetics ofcross-linik formation and removal
have been found to be generally similar. After treatment of
cells with melphalan at doses equivalent to those used in the
present study, maximim cross-link-ing is observed at 4-6 h
with extensive evidence of repair at 24 h post treatment
(Zwelling et al., 1979b; O'Connor & Kohn, 1990). Similarly,
treatment of cells with a wide range of doses of cisplatin
results in a peak of cross-linking at 6-12 h (Zwelling et al.,
1978). The removal of cross-links is faster after treatment
with higher doses of cisplatin (Pera et al., 1981). In contrast,
the cross-linking observed in the present study by 1 con-
tinued to increase to a peak at 24h following a I h drug
treatment with no evidence of removal at 36 or 48 h.
The apparent lack of repair of 1-induced cross-links may
be due to an equilibrium reached between cross-link forma-
tion and repair in the cells. Alternatively, it may be that these
lesions in the minor groove of DNA are not recognised by
the same repair enzyme complexes that recognise and repair
melphalan and cisplatin cross-links in the major groove of
DNA. Previous nuclear magnetic resonance (NMR) and
molecular modelling studies have demonstrated that the com-
plex of 1, with its optimum binding sequence of 5'-
PuGATCPy and the drug cross-linked symmetrically via the
N2-guanine positions, provides minimal distortion of the
DNA helix (Bose et al., 1992b). Such a complex may then
not be recognised by a DNA repair mechanism which is
scanning for distortion of the DNA.
Studies in the characterised pairs of sensitive and resistant
cell lines were undertaken to assess the factors which may
affect the sensitivity of cells to 1. The results obtained would
appear to be related to the major mechanism associated with
the resistance of each line. 4IMcisR and HX155cisR are
resistant mainly because of decreased uptake of cisplatin,
while CHIcisR is resistant because of enhanced DNA repair
of platinum adducts (Kelland et al., 1992; Mellish et al.,
1993). No cross-resistance to 1 was observed in the former
lines, indicating that uptake of isplatin and 1 are by
different mechanisms. Compound 1 retained partial activity
against CHlcisR, suggesting that some elements of the
enhanced repair of platinum adducts may be involved in
repair of 1. The A2780cisR line has been shown to possess a
combination of elevated glutathione, increased DNA repair
and decreased uptake (Behrens et al., 1987). With this line, 1
showed a similar (14-fold) level of resistance to asplatin. By
comparison with the 41McisR and HX155cisR lines, drug
uptake is not thought to be involved in the resistance to 1.
Similarly, enhanced DNA repair is not thought to play a
major role since no evidence of repair of 1-induced cross-
links was observed in this cell line at 48 h. The partial
reversal of the resistance to 1 in the A2780cisR line by GSH
depletion using BSO (with resultant incrase in interstrand
cross-linking) indicates that resistance is largely due to inac-
tivation of the drug by GSH binding in cells. Further
evidence for this is provided by the comparative ICv data for
the HX62 (0.3aiM) vs 41 M (0.04pM) cell lines, as previous
studies have shown a 4-fold higher GSH level in the HX62
cells (Mistry et al., 1991). Previous studies have already
shown that PBDs react with thiol-containing nucleophiles
such as thiophenol to give stable covalent adducts (Morris et
al., 1990; Morris, 1992).
Both cell lines with acquired resistance to doxorubicin
(4lMdoxR) showed full or partial cross-resistance to 1. High
levels of cross-resistance have also been observed to vinblas-
tine, colchicine and taxol in these cell lines, which possess
elevated levels of p170 glycoprotein. Compound 1 is,
therefore, a substrate for this multidrug efflux mechanism,
which was confirmed by the partial reversal of resistance in
the presence of the calcium channel blocker verapamil.
Compound 1 is, therefore, the most cytotoxic compound in
a series of rationally designed PBD-based sequence-selective
DNA minor-groove cross-linking agents. It is a highly
efficent interstrand cross-linkling agent in cells, and the cross-
links appear to be difficult to repair. Levels of glutathione
and p170-glycoprotein clearly determine the sensitivity of
cells to 1. Further investigation will determine how much
these factors affect the efficacy of 1 in vivo.
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